The manufacturer of semaglutide, Novo Nordisk, has sponsored a placebo-controlled interventional trial (EVOKE) comparing the effects of semaglutide to placebo (dummy medicine) on early Alzheimers disease
Additionally, the study does not allow researchers to extrapolate semaglutides effects outside of concomitant medications, according to Lyons
In the landmark FLOW clinical trial published in the New England Journal of Medicine, Semaglutide (Ozempic) reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease
In animal studies, melatonin decreases brain insulin resistance.[ref] Melatonin levels decrease with aging, while the risk of Alzheimers is greatly dependent on age
H.JungS
A tasty way to support energy, metabolism, and digestion vitafusion GLP-1 Support Multivitamin gummies make wellness routines easyand delicious